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1. ABSTRACT 
 
 
 
Neurological disorders associated with the X-linked kinase CDKL5 are characterized by the 
early onset of seizures, severe cognitive deficits and autistic traits. No curative therapy exists 
for these patients and treatments are only focused on alleviating symptoms. Loss of Cdkl5 
affects spine density and stabilization as well as synaptic activity, but the underlying 
molecular mechanisms are still far from fully understood.  
Here we show several pieces of evidence linking Cdkl5-associated synaptic defects to AMPA 
receptor (R) expression and subunit composition. In particular, primary hippocampal 
neurons devoid of Cdkl5 have defective GluA2-subunit expression, as well as a hyper-
phosphorylation of Serine 880 (S880). Moreover, Cdkl5-downregulation skews the 
composition of membrane-inserted AMPARs towards the GluA2-depleted calcium-
permeable form. The depletion of membrane-inserted GluA2 is likely to rely on defective 
recycling. Indeed, at the molecular level, we find that CDKL5 interacts with GRASP-1, a 
neuron-enriched protein that coordinates the endosomal sorting of AMPARs towards the 
plasma membrane. Against this background, we assume that the resulting alterations can 
underlie, at least in part, the synaptic dysfunctions and cognitive deficits in CDKL5 disorder. 
Finally, we provide evidence that tianeptine, a promising drug previously reported to 
modulate AMPAR-mediated glutamatergic neurotransmission, is capable of restoring 
GluA2 expression and S880 phosphorylation in neurons devoid of CDKL5. These results 
places tianeptine as an interesting candidate drug for CDKL5-disorder, the therapeutic 
potential of which will be further investigated.
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2. INTRODUCTION 
 
 
 
2.1 CDKL5 disorder: from the discovery of the gene to the characterization of the 
disease 
The Cyclin-Dependent Kinase-Like 5, CDKL5 (Mendelian Inheritance in Man, MIM: 300203), 
was identified in 1998 by Montini and colleagues (1) through positional cloning studies 
aimed to isolate disease genes located in Xp22 where a number of human genetic disorders 
had formerly been mapped including Nance-Horan (NH) syndrome, oral–facial–digital 
syndrome type 1 (OFD1) and nonsyndromic sensorineural deafness (DFN6).  
Since CDKL5 sequence analysis revealed homologies to several serine-threonine kinases, the 
protein was initially named STK9 (Serine Threonine Kinase 9) but, after sequence 
comparisons, the STK9 gene was renamed CDKL5 because of the strong similarity to cyclin-
dependent kinases (2).  
In 2003, Vera Kalscheuer linked chromosomal rearrangements involving CDKL5 with severe 
intellectual disability and early onset seizures (2). In the following year, different CDKL5 
mutations were described in individuals with infantile spasms, mental retardation and 
clinical manifestation similar to Rett syndrome (RTT) (3, 4); CDKL5 was thus proposed as a 
novel gene implicated in the “early seizure variant” of RTT, also known as the Hanefeld 
variant in honor of the physician who described it for the first time in 1985 (5).  
At first, screenings for CDKL5 mutations were focused on cohorts of female patients with a 
clinical phenotype mimicking RTT, which is in most cases caused by mutations in the X-linked 
MECP2 gene. Many of the early-onset encephalopathies have overlapping phenotypes (6, 7). 
Some are distinctive either by dysmorphism or typical neurodevelopmental profile, but 
others, including CDKL5 disorder, at first may be less easily recognized, which is why they 
were classified as “variant” of others syndromes. To date, studies performed on a larger 
number of individuals with CDKL5 disorder have better characterized the spectrum of 
clinical presentations and confirmed that this disease is an independent clinical entity (8, 9). 
Clinical features characterizing CDKL5 disorder include early-onset seizures (generally 
appearing within 3 months of life), severe global developmental delay, abnormal muscle 
tone, hand stereotypies, gastrointestinal problems and bruxism (Table 1) (8). Moreover, 
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subtle but shared dysmorphic features have also been described in individuals with a CDKL5 
mutation such as a prominent/broad forehead, deep-set but large-appearing eyes, full lips 
and tapered fingers; these traits can be useful for clinicians in determining whether the 
patient warranted CDKL5-specific mutation testing. Variability in clinical features has also 
been reported since some individuals are less severely affected in terms of motor skills and 
expressive communication (10, 11). Those differences can be partially due to X-inactivation, 
resulting in a mosaic expression of normal and mutant CDKL5 protein. As a matter of fact, 
males with CDKL5 mutations tend to be more severely affected than females. 
 
 
Table 1| Clinical features suggesting a diagnosis of the CDKL5 disorder according to (8). 
 
2.2 CDKL5/Cdkl5 gene, isoforms and their expression in brain 
The knowledge of CDKL5 transcripts and isoforms and their developmental expression 
profile is essential for understanding the mechanistic roles of the kinase in brain 
development. Since the discovery of the CDKL5 gene, the characterization of its transcripts 
and the resulting protein isoforms remained incomplete; however, recently Hector and 
colleagues (12) systematically outlined human CDKL5 and mouse Cdkl5 mRNA products and 
predicted the protein isoform translated from each transcript (Table 2).  
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According to the current knowledge, the human CDKL5 gene occupies approximately 240 kb 
of the Xp22 region and is composed of 24 exons and its expression comprises five major 
transcript isoforms: hCDKL5_1-5. Consistent with a previous publication (13), hCDKL5_1 
(formerly known as CDKL5107) appears to be the most abundant transcript in the CNS, while 
hCDKL5_2-4 represent less than 15% of CDKL5 transcripts expressed in the whole brain and 
hCDKL5_5 (formerly CDKL5115), in the adult, is only detected in testis. The murine transcript 
mCdkl5_1 appears to be completely orthologous to its human counterpart and is also the most 
abundant Cdkl5 transcript in mouse brain.  
Analyses of human transcript expression profiles during development revealed that 
hCDKL5_1-4 are expressed at higher levels in the adult than in the foetal brain. Conversely, 
hCDKL5_5, which, in the adult, is expressed only in testis, is, however, expressed in foetal 
human brain. The expression of Cdkl5 across a developmental time series revealed that 
mCdkl5_1 and mCdkl5_2 are expressed throughout murine brain development, increasing in 
levels and peaking within the first few postnatal weeks, with mCdkl5_1 expressed at higher 
levels than mCdkl5_2 as previously noted.  
 
 
          Table 2| Summary of CDKL5/Cdkl5 isoforms and nomenclature (12). 
 
A detailed analysis of Cdkl5 expression in adult mouse brain showed that its mRNA is 
particularly abundant in the forebrain. In particular, higher expression levels are detected in 
most superficial cortical layers involved in the intercortical connectivity. Interestingly, Cdkl5 
mRNA expression is more evident in the frontal cortex, motor cortex and cingulate gyrus, 
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suggesting the involvement of CDKL5 in mental diseases related to the physiological role of 
these areas. Moreover, high expression levels are detected also in all CA fields of 
hippocampus and in the entorhinal cortex pointing out that CDKL5 might be involved in 
higher cognitive functions like learning and memory. Looking at the cellular level, Cdkl5 
transcripts seem to be expressed mostly in glutamatergic and GABAergic neurons, while very 
low expression is detected in dopaminergic and noradrenergic neuronal populations 
(reviewed in 11). Finally, recent data from our laboratory revealed that Cdkl5 mRNA is 
distributed throughout neuronal districts even in spines, where local translation may 
participate in spine dynamics (15). 
 
2.3 CDKL5 protein 
CDKL5 is a member of the CMGC serine/threonine protein kinase group, which shares 
homologies with mitogen-activated kinases (MAPK) and cyclin-dependent kinases (CDK). 
CDKL5 is characterized by a N-terminal serine/threonine catalytic domain (aa 13-297), 
which comprises an ATP-binding region (aa 13-43) and a protein kinase active site (aa 131-
143) (reviewed in 11). Within the catalytic domain is also present a Thr-X-Tyr (TEY) motif 
(aa 169-171) whose dual phosphorylation is reported to activate, among others, kinases of 
the MAPK family (16). CDKL5, as some other proteins of the CMGC group, can 
autophosphorylate its TEY motif. Despite CDKL5 is known to exist as a number of different 
isoforms, they all share the same catalytic domain, whereas differences are found in the C-
terminus of the protein. An unusual long C-terminal tail, which plays an important role in 
regulating the subcellular localization, is unique for CDKL5. As a matter of fact, putative 
signals for nuclear import (NLS1 aa 312-315; NLS2 aa 784-789) and export (NES 836-845) 
have been recognized in the C-terminal tail (Image 1).  
At the cellular level, CDKL5 can be detected in all NeuN-positive neurons, while it is expressed 
at very low levels in glia. As previously mentioned, CDKL5_1 is the most expressed isoform 
in brain and its functions seem to be regulated both through subcellular localization, 
synthesis, and degradation. In cortex, CDKL5 is equally distributed between nucleus and 
cytoplasm but studies performed in cultured hippocampal neurons revealed that specific 
stimuli can induce the translocation of CDKL5 from the nucleus to the cytoplasm through an 
active nuclear export mechanism mediated by the CRM1 receptor (17, 18).  
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Proteasome-dependent degradation has been reported to be involved in modulating CDKL5 
levels. Publications from our laboratory showed that sustained stimulation with both 
glutamate and KCl strongly reduce Cdkl5 levels in primary hippocampal cultures; this 
reduction, which occurs after a short-lasting induction of Cdkl5 protein synthesis, was 
prevented by the application of the proteasome-inhibitor MG132. It is worthwhile to note 
that MG132 treatment alone resulted in an increase of Cdkl5 levels, indicating that the 
proteasome constitutively regulates the turnover of the protein (15, 17). Moreover, it has 
been shown that Cdkl5 interacts Mind bomb 1 (Mib1), an E3 ubiquitin ligase, that concurs in 
regulating neurite outgrowth in post-mitotic neurons, as well as long-term potentiation and 
synaptic plasticity in mice (19–21). Mib1 overexpression leads to a strong downregulation of 
CDKL5 in a dose dependent manner, suggesting that the Mib1 ligase activity is required for 
the proteasome-dependent induced change of CDKL5 abundance (19). 
 
 
Image 1| Schematic representation of hCDKL5_1 with the functional domains and signatures indicated. NLS: 
nuclear localization signal; NES: nuclear export signal. Kinase domain is depicted in blue. Numbering refers to 
amino acid. 
 
2.4 CDKL5 pathological variants 
To date, 245 different CDKL5 variants have been described in literature (RettBASE: 
RettSyndrome.org Variation Database mecp2.chw.edu.au. Accession date: February, 2017) 
(22). Among these, 161 were classified as pathogenic or likely pathogenic variants, including 
missense and nonsense mutations, splice variants, exonic deletions, in-frame or frameshift 
mutations and multiple mutations (combinations of nonsense and missense mutations in the 
same patient) (Table 3). Moreover, Xp22 duplications involving CDKL5 gene have been 
described (23). 
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Table 3| Summary of CDKL5 pathogenic or likely pathogenic variants reported in         
RettBASE (22) (Accession date: February, 2017). 
 
Notably, missense mutations localize mainly in the catalytic domain underscoring the 
importance of the kinase activity of CDKL5 for proper brain functions. On the contrary, 
truncating mutations can occur anywhere in the gene, resulting, if the transcript does not 
undergo nonsense-mediated decay, in CDKL5 derivatives of various lengths. Several studies 
have tried to elucidate the molecular effects of CDKL5 pathological mutations through the 
overexpression of CDKL5 mutants in non-neuronal cell lines (18, 24, 25). These studies 
revealed that missense mutations impact negatively on the catalytic activity of CDKL5, while 
C-terminally truncated derivatives prevalently localize in the nucleus. It is important to 
mention that the C-terminal tail also acts as a negative regulator of catalytic activity. Whether 
CDKL5 C-terminal mutants act as loss- or gain- of function proteins is still to be understood. 
Since CDKL5 exerts its roles both in the cytoplasm and in the nucleus, the absence of 
truncated derivatives from the cytoplasm might be involved in the pathological phenotypes.  
The limited number of patients still hampers drawing any genotype-phenotype correlation. 
Recently, Fehr and colleagues analysed the existence of a correlation in the largest number 
of CDKL5-confirmed cases (124 patients) harbouring different mutations (26). They found 
that those patients with late truncating mutations in the C-terminal domain (with a 
truncation after aa 781) had better communication skills and were more likely to be able to 
stand or walk independently than those predicted to have no functional protein. Clearly, 
larger studies are needed to better investigate the roles of different CDKL5 variants on 
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protein expression, function, and on the clinical phenotype. Finally, also the increased dosage 
of CDKL5 due to genomic duplication concurs in clinical manifestations, including difficulties 
in learning, autistic and hyperactive behaviour, developmental and speech delay, and 
macrocephaly. All these data suggest that unbalanced CDKL5 expression and activity can lead 
to perturbations of synaptic development and plasticity. 
 
2.5 Roles of CDKL5 in synaptic function, morphology and plasticity 
Growing pieces of evidence have accumulated supporting the hypothesis that CDKL5 is 
directly involved in neuronal functions and plasticity. Firstly, CDKL5 expression correlates, 
both in vivo and in vitro, with neuronal maturation and remains high in the adulthood (18), 
suggesting that the kinase might play a role not only in neuronal maturation but also in 
maintaining neuronal functions. 
Interestingly, recent data from our laboratory demonstrated that CDKL5 levels respond 
promptly to neuronal activity and the kinetics of protein expression and decline are tightly 
regulated and change dramatically between different developmental stages (15). As a matter 
of fact, KCl-induced CDKL5 up-regulation is maintained for a longer time after stimulation in 
immature neurons, whereas at further stages of maturation the expression of the kinase 
return to basal levels, or even lower, within few minutes. Moreover, activation of local protein 
synthesis in dendrites and spines seems to be the main mechanism involved in the stimulus-
dependent regulation of CDKL5 expression and rely, in mature neurons, on calcium influx 
through NMDA and AMPA receptor. Furthermore, NMDA receptor activation is mandatory 
for the subsequent PP1-dependent CDKL5 dephosphorylation and rapid degradation. CDKL5 
thus behaves similarly to cAMP response element-binding protein (CREB), a transcription 
factor widely known to be implicated in synaptic plasticity, the expression and 
phosphorylation status of which rely on NMDA receptor activation (27).  
The co-localization of CDKL5 with post-synaptic density protein 95 (PSD95) and SHANK, 
both in vitro and in vivo, and its juxtaposition to VGLUT, led Ricciardi and colleagues to relate 
CDKL5 to glutamatergic synapses (28). Synaptic targeting of CDKL5 seems to be regulated 
both by the presence of its mRNA that undergoes local translation upon stimuli, as mentioned 
above, and the direct interaction with synaptic proteins such as PSD95 and netrin-G1 ligand 
(NGL-1) (28, 29). PSD95 is a post-synaptic scaffolding protein that regulates synaptic 
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accumulation of its binding partners. For instance, AMPA receptor targeting and stabilization 
at the post-synaptic membrane is mediated by PSD95 through the direct interaction with the 
AMPA receptor interacting protein stargazin. Similarly, CDKL5 synaptic targeting is 
promoted by its interaction with the palmitoylated form of PSD95 or by the formation of a 
complex involving PSD95 and NGL-1. NGL-1 is a regulator of synapse formation and 
homeostasis and its phosphorylation at serine 631, mediated by CDKL5, is necessary to 
ensure stable binding to PSD95. The synaptic targeting of CDKL5 suggests its involvement in 
molecular pathways that regulate synaptic maturation and function. As a matter of fact, RNA 
interference analyses showed that loss of CDKL5 affects spine morphology and excitatory 
synaptic functions. Consistent data showed that CDKL5-knock down, both in vitro and in vivo, 
results in phenotypical filopodia-like immature spines, reduced excitatory synaptic puncta 
and decreased amplitude and frequency of miniature excitatory post-synaptic currents 
(mEPSCs) (28, 29).  
To study CDKL5 loss-of-function in vivo, two independent laboratories have generated Cdkl5-
null mouse models that mirror some clinical aspects of the human disease (30, 31). In 
particular, the Wang model shows motor defects, reduced anxiety, decreased sociability, 
altered EEG activity, and impaired learning and memory, which are core features of CDKL5-
related disorder (30). These ethological phenotypes mimic the impaired motor skills, 
reduced social interaction and intellectual disability observed in CDKL5 patients. 
Interestingly, neither of the two mouse models shows the characteristic onset of spontaneous 
seizures even though Amendola and colleagues demonstrated an abnormal EEG response 
upon treatment with the pro-convulsant kainic acid (31). Importantly, the absence of an 
epileptic neuronal network suggests that the behavioural and electrophysiological defects 
observed in these mice are primary consequences of CDKL5 loss-of-function.  
Notably, serine/threonine kinome studies on Cdkl5-null brains revealed alterations of many 
signal transduction pathways, including that of AKT-mTOR, which has been implicated in the 
etiology of autism spectrum disorders and RTT. In addition to the AKT-mTOR pathway, loss 
of CDKL5 alters the phosphorylation profile of other kinases involved in synaptic plasticity 
including PKA, PKC and PKD (30). These alterations may be indirect effects of CDKL5-loss, 
but suggest once more that CDKL5 is crucial for the coordination of multiple signalling 
pathways involved in synaptic plasticity.  
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Similarly to CDKL5 RNA-interference experiments, Cdkl5-null brains show a decrease in 
excitatory synaptic puncta in the CA1 field of hippocampus as result of a lower spine density. 
Moreover, immunohistochemical characterization of spine shape revealed a higher 
percentage of immature spines (filopodia, thin- and stubby-shaped) in Cdkl5-/y neurons 
compared to wild type neurons (32). To dissect out the role of CDKL5 in spine formation, 
stability and elimination during development, Della Sala and colleagues have taken 
advantage of cranial window implantation overlying the somatosensory cortex followed by 
two-photon imaging at different time points (33). During early development, Cdkl5-null 
brains display significant reduction of spine density and PSD95-positive puncta when 
compared to wild type littermates. Conversely, the density of filopodia was similar between 
the two genotypes, suggesting that CDKL5 is not involved in the formation of new spines but 
rather in the stabilization of mature mushroom-shaped spines. As matter of fact, the 
decreased spine density in Cdkl5-/y mice can be attributed to lower spine survival rate. As 
result, the authors showed a dramatic decrease in mEPSCs frequency and long-term 
potentiation impairment in Cdkl5-null cortical slices.  
Altogether, these data suggest that CDKL5 can be considered as a new plasticity molecule 
that seems to be crucial for the regulation of spine dynamics and for learning and memory. 
 
2.6 AMPA receptor structure and subunit composition 
More than forty years have passed since Bliss and Lømo used rabbit hippocampi to 
demonstrate for the first time that a stimulus could cause an increase in synaptic strength 
that was long lasting, named long-term potentiation (LTP)(34). The discovery of LTP laid the 
foundation for a remarkable number of studies aimed to understand how memories are 
stored in synapses and whether changes in these structures underlie the ability to learn new 
behaviours.  
A particular class of glutamatergic receptors, the cation-permeable ionotropic alpha-amino-
3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors (AMPARs), mediate most 
fast excitatory synaptic transmission in the central nervous system and are one of the key 
determinants of synaptic strength and plasticity (35). AMPARs are expressed throughout the 
brain and are composed by four subunits (GluA1-GluA4), also known as GluR1-GluR4, which 
are encoded by the genes GRIA1-GRIA4, and are assembled as dimers-of-dimers to form 
15 
 
homo- or hetero-tetramers (Image 2-A) (36). Most AMPARs in adult hippocampus and cortex 
consist of GluA1 plus GluA2 or GluA2 plus GluA3 subunits, but since GluA3 is expressed at 
relatively low levels, GluA2 is prevalently found associated with GluA1 (37, 38). Contrariwise, 
GluA4 is tightly developmentally regulated and is barely expressed in the adult brain where 
it is a key determinant of AMPAR-mediated transmission in parvalbumin-containing 
inhibitory interneurons (39–41).  
All AMPA receptor subunits comprise an extracellular amino-terminal domain (ATD or NTD), 
a ligand binding domain (LBD) (S1 and S2), three membrane-spanning domains (M1, M2 and 
M3), one cytoplasmic re-entrant loop (P), and an intracellular carboxy-terminal domain 
(CTD) (Image 1-B) (36, 42, 43). The extracellular and transmembrane domains are highly 
homologous whereas the main differences can be found in the intracellular cytoplasmic tails. 
GluA1 and GluA4 have long cytoplasmic tails, whereas GluA2 and GluA3 have short C-
terminal tails. Alternative splicing can generate different splice forms of GluA2 and GluA4, 
named GluA2L and GluA4S, characterized by a longer (L) or shorter (S) tail (44, 45). 
Moreover, alternative splicing also generates the flop (shorter) and flip (longer) variants of 
AMPARs, encoded by exon 14 and 15, respectively, that differ by a 38-amino-acids insertion 
in the LBD. While the expression of the flop variants increases during development, the 
expression of the flip variant remains prominent and unchanged not only in the post-natal 
development but also during gestation (46, 47). 
 
2.7 Biophysical and molecular properties of AMPA receptors 
The release of the neurotransmitter glutamate from the presynaptic density activates post-
synaptic ion channels including AMPARs, N-methyl D-aspartate (NMDA) and kainate (KA) 
receptors. Once activated, the glutamate-gated ion channels flux sodium (Na+) and in some 
cases also calcium (Ca2+). NMDARs are uniformly Ca2+-permeable (48), whereas AMPARs and 
KA receptors exist in both Ca2+-permeable and -impermeable forms depending on the precise 
subunit composition and RNA editing. In the adult brain, almost all GluA2 (~99%) have a 
positively charged arginine (R) in the M2 channel-forming segment at position 607 (Q/R site) 
(Image 1-B), while other AMPAR subunits have glutamine (Q) at this position (49). This 
difference is caused by RNA-editing in which the site-selective deamination of adenosine (A) 
in the critical CAG codon in the pre-mRNA to an inosine (I) creates a CIG codon (50). Since 
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the ribosomes read the inosine as a guanosine (G), the edited codon alters the coding 
potential and an R is inserted in place of Q. The resulting edited GluA2(R) prevents Ca2+ influx 
when it is incorporated in the AMPAR. Conversely, AMPARs containing unedited GluA2(Q) 
are highly permeable to Ca2+. When glutamine is present, a negative electrostatic potential is 
formed with the N-terminus of the M2 loop and cations are thus attracted. However, the 
replacement of the neutral glutamine with a large positively charged arginine residue 
neutralizes the negative electrostatic potential and thus prevents the diffusion of divalent 
cations through the pore (51). Deamination is performed by ADAR2, a double-stranded-RNA-
specific adenosine deaminase and the principal RNA-editing enzyme in mammals (50). 
Unedited GluA2(Q) exists during embryogenesis where it seems to have an important role in 
directing human neural progenitor cell differentiation to neurons (52). 
The precise number and subunit composition of AMPARs determine the efficiency and 
dynamics of AMPAR-mediated synaptic signalling, in particular, different subunit 
composition confer distinct biophysical and molecular properties to AMPARs. For example, 
GluA2-containing receptors display a linear current-voltage relationship and are 
impermeable to Ca2+ (53). In contrast GluA2-lacking receptors display double rectification, 
have higher single-channel conductance and are Ca2+-permeable (54). Moreover, flip/flop 
variants influence the response to AMPAR potentiators, with flop versions being less 
responsive and de-sensitizing more rapidly to glutamate than flip variants (46, 55, 56). 
 
2.8 AMPA receptor-interacting proteins 
AMPAR trafficking, synaptic targeting and recycling relies on interactions with a large 
number of proteins comprising those that interact alternatively with the NTDs and CTDs. 
 
2.8.1 NTD-interacting proteins 
To date only two proteins have been described to interact with the NTD of all four AMPAR 
subunits: neuronal pentraxin 1 (NP1) and neuronal immediate early gene neuronal activity-
regulated pentraxin (NARP). While NP1 is important in homomeric GluR4 clustering during 
synaptogenesis, NARP is fundamental for GluA1-, GluA2- and GluA3-AMPAR clustering and 
stabilization at excitatory synapses (57, 58). GluA2 NTD has also a specific interaction site for 
N-cadherin, an important transmembrane protein, which concurs in pre- to post-synaptic 
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adhesion. GluA2 NTD is required non only for morphological spine changes in length and 
width but also for spine number, suggesting that GluA2-containing AMPAR may stimulate 
spine formation and development through structural interaction at the synaptic junction (59, 
60). 
 
2.8.2 CTD-interacting proteins 
PDZ (Post-synaptic density 95/Discs large/Zona occludens 1) domain-mediated protein 
interactions have been shown to play important roles in the regulation of glutamate receptor 
function at excitatory synapses. In the cytoplasmic compartment, several PDZ-containing 
molecules interact with the CTD of AMPARs (Image 1-C). SAP97, a member of the membrane-
associated guanylate kinase (MAGUK) family, binds simultaneously the C-terminus of GluA1 
through its PDZ domain and AKAP79 (protein kinase A anchoring molecules), which may 
promote GluA1 phosphorylation required for LTP (61–63). Moreover, SAP97 has also been 
described to act in the early secretory pathway to facilitate AMPAR maturation (64). GluA2 
and GluA3 share a C-terminal sequence (SVKI), which interacts with the PDZ-containing 
molecules GRIP1, GRIP2 (ABP), and PICK1. To date, several studies have shed light on the 
important roles of GRIP1/2 and PICK1 in AMPAR trafficking and synaptic plasticity (65–67). 
Other non-PDZ-containing molecules are able to interact with AMPARs in a subunit-specific 
manner (Image 1-C). Among these, 4.1N protein, the neuronal isoform of red blood cell actin 
cytoskeleton associated protein 4.1R, appears to be involved in AMPAR stabilization at the 
cell surface by the interaction with GluA1 (68). On the other hand, the interaction between 
the ATPase NSF and GluA2 is required for the insertion and subsequent stabilization of 
GluA2-containing AMPARs in the membrane (69), while AP2 interaction, in a region 
overlapping the NSF binding site, is involved in clathrin-mediated endocytosis during LTD 
(70). 
Among the large number of CTD-interacting protein there is another group of molecules 
named AMPA auxiliary proteins, which are important for AMPAR targeting and stabilization 
at the post-synaptic membrane. This group of molecules includes the transmembrane AMPA 
regulatory proteins (TARPs)(71–73). TARPs are classified into six isoforms - type 1a (γ-
2/stargazin and γ-3), type 1b (γ-4 and γ-8) and type 2 (γ-5 and γ-2) - according to how they 
control AMPAR trafficking and channel properties. Owing to incompatible PDZ ligands, 
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AMPARs do not bind directly to the synaptic scaffold protein PSD95. Instead, TARPs bind to 
PSD95 like MAGUK proteins to stabilize the AMPARs at the post-synaptic membrane. 
Moreover, TARPs differentially modulate channel properties not only by selectively 
stabilizing specific AMPAR channel conformations, but also by altering the structure of the 
AMPAR pore (74). 
 
 
Image 2| (A) Schematic illustration of AMPAR tetramer in membrane. Tetrameric AMPARs are assembled from 
two dimers of distinct subunit composition. (B) Schematic illustration of the GluA subunit structure. Each 
subunit has an extracellular amino-terminal domain (ATD or NTD), three full trans-membrane domains (M1, 
M2 and M3), an intracellular re-entrant loop, which is the site of Q/R editing in GluA2, and an intracellular 
carboxy-terminal domain (CTD). Each GluA subunit is composed of a large extracellular ligand-binding core 
(segments S1 and S2) that serves as binding site for glutamate. In red is depicted the site of the alternative splice 
19 
 
flip and flop variants that control gating kinetics. (C) Sequences of the intracellular CTDs of the predominant 
isoforms of human GluA1 and GluA2 indicating protein interaction sites (in green), phosphorylation sites (in 
blu) and a palmitoylation site (underlined). 
 
2.9 AMPA receptor biosynthesis and trafficking 
Similarly to most multimeric trans-membrane proteins, AMPARs are first assembled in the 
endoplasmic reticulum (ER). The initial dimerization is a heterodimer assembly, which 
preferentially incorporates GluA2 subunits in the nascent receptor; however, dimerization of 
GluA2-lacking AMPARs is also possible under appropriate physiological and pathological 
conditions (75–77). This initial process involves the interaction between the NTDs of two 
subunits, followed by a second dimerization step that is mediated by associations at the LBD 
(78). Against this background, most assembled AMPAR tetramers contain GluA2 subunits 
that profoundly influence receptor trafficking, slowing ER export of new receptors. AMPARs 
that contain both GluA1 and GluA2 subunits exit rapidly from the ER overriding the ER 
retention of GluA2 whereas GluA2/GluA3 homo/heteromers transit much slower (49, 79). It 
is important to recall that the GluA2 subunit is strongly regulated by Q/R editing and the 
arginine arising from this event of maturation influences not only channel properties but also 
receptor trafficking. Unedited GluA2(Q), whenever present, traffics rapidly through the ER 
similarly to GluA1. The Q/R editing results in a stable pool of GluA2 subunits that exit the ER 
in a heteromeric complex in a more regulated manner (49). 
As previously described, AMPARs can interact with many proteins through their CTD, and 
some of these proteins may regulate ER retention or exit. Among these proteins, PICK1 is not 
only involved in AMPAR endocytosis and/or recycling but seems also to be necessary for the 
exit of GluR2 from the ER while SAP97 seems to have the same function towards GluR1 (80, 
81). AMPAR biosynthesis and the secretory pathway involve not only the somatic Golgi 
apparatus but also the dendritic Golgi compartments representing the outposts of post-
translational modifications of proteins that are translated locally (82). Within the Golgi, 
AMPAR subunits and AMPAR-associated proteins undergo lipid modifications and, between 
these, palmitoylation plays important roles in synaptic function (83, 84). Palmitoylation is a 
reversible process regulated by palmitoyl acyl transferases that attach covalently palmitate 
moieties via a thioester bond to cytosolic cysteine residues. PSD95 and GRIP1/GRIP2 
20 
 
pamitoylation positively regulate AMPAR accumulation at synapses and AMPAR trafficking 
toward the membrane (84–86). AMPA receptor palmitoylation can occur on a cysteine near 
the Q/R editing site and in the CTD (87). Palmitoylation of AMPAR CTD negatively regulate 
the interaction with 4.1N resulting in a minor surface expression and increased 
internalization (68). 
The architecture of neurons, which are characterized by high polarization and an elaborate 
structure, poses the problem for the trafficking of membrane proteins, including AMPARs, 
that is further exacerbated by the very long distances between the soma and their final 
locations. AMPARs are trafficked along dendrites in a microtubule-dependent manner; this 
transport is an active process involving motor proteins such as kinesin and dynein (88). The 
PDZ-containing proteins GRIP1/GRIP2 interact directly with the heavy chain of kinesin 
(KIF5) together with the CTD of GluA2/GluA3 subunits (89). Moreover, the KIF1-interacting 
protein Liprin-α can bind GRIP1/2-GluR2 complex suggesting that GRIP1/GRIP2 proteins 
serve as an adaptor to link AMPAR to kinesins and promote dendritic transport (90). In 
addition, neurons have evolved specific pathways to transport mRNA into dendrites, where 
subsequent local translation can occur. Most mRNAs transported into dendrites are those 
encoding proteins involved in synaptic transmission, such as Arc, calcium/calmodulin 
protein kinase II (CamKII), brain-derived neural factor (BDNF) and some AMPAR subunit 
mRNAs, suggesting that local synthesis of AMPAR subunits regulates local receptor 
abundance and composition (91). Notably, the group of mRNAs that undergo stimulus-
dependent local translation has recently been found to comprise that of CDKL5 (15). 
 
2.10 AMPAR trafficking in LTP and LTD 
Hebbian plasticity is a mechanism that gives rise to long-lasting changes in synaptic strength, 
including LTP and LTD. These opposite phenomena both start with presynaptic terminal 
depolarization and subsequent activation of NMDA receptors, which allows Ca2+ entrance at 
the post-synaptic site. A strong but brief increase in Ca2+ concentration gives rise to LTP, 
whereas a low but continuous Ca2+ influx promotes LTD (92, 93). Intracellular Ca2+ acts on 
several signalling pathways including those involving kinases, such as, calcium/calmodulin 
protein kinase I and II (CamKI/II), cAMP-dependent PKA and PKC, but also phosphatases, 
such as protein phosphatase 1 (PP1), 2A (PP2A) and 2B (PP2B). Both kinases and 
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phosphatases regulate AMPAR trafficking to and from the post-synaptic membrane, 
influence AMPAR composition over longer term, affect pre-existing post-translational 
modifications influencing channel permeability and, finally, regulate the interactions 
between AMPARs and AMPAR-interacting proteins (44). 
LTP is characterized by the long-lasting potentiation of AMPAR-mediated excitatory post-
synaptic currents (EPSCs). An emerging consensus is that the transient membrane 
expression of calcium-permeable AMPAR (CP-AMPAR), those arising from either the lack of 
GluR2 subunits or from the presence of unedited of GluA2, contributes to the induction, but 
not the maintenance, of LTP (94–96). During LTP induction, CP-AMPARs are recruited to 
synapses from perisynaptic sites to contribute to Ca2+ entry followed by NMDAR activation. 
This results in stimulation of CamKII, PKA and PKC that catalyze GluA1 phosphorylation 
(Image 1-C). The phosphorylation state of GluA1 is critical for AMPAR recruitment to post-
synaptic sites. Specifically, four serine residues can be phosphorylated during LTP (Ser831 
by CAMKII and PKC; Ser845 PKA; Ser816 and Ser818 by PKC). These phosphorylation events 
not only enhance the binding of GluA1 to 4.1N, which stabilizes the receptor at the post-
synaptic density, but also increase the conductance and opening probability of the channel 
(reviewed in 64).  The Ca2+ that is gated from CP-AMPARs contribute the recruitment of CI-
AMPARs, containing edited GluA2 subunits. Until CP-AMPARs are replaced with CI receptors, 
LTP remains unstable and easily reversible. It should be noted, however, that the 
involvement of CP-AMPARs in LTP is not universally accepted (98, 99); therefore the roles, 
the timing and extent of CP-AMPAR/CI-AMPAR incorporation in the post-synaptic membrane 
during LTP still remain an open field of research. 
Contrariwise, LTD is characterized by the loss of synaptic AMPARs evoked by NMDARs or 
metabotropic glutamate receptor activation (92). Upon NMDA stimulation, GluA2-containing 
AMPARs diffuse laterally to extrasynaptic sites where they are internalized in a clathrin-
dependant manner via the clathrin adaptor AP2, which promotes the assembly of a clathrin 
coat (70). AP2 binds a region overlapping the NSF interaction site within GluA2 and during 
LTD the affinity of GluA2 for NSF is lost allowing the binding of AP2, which promotes AMPAR 
internalization (70). Several other GluA2-interacting proteins have been shown to regulate 
AMPAR trafficking in LTD; between these, GRIP1/2 and PICK1 are the best characterized (65, 
100). While GRIP1/2 promote GluA2 surface stabilization and recycling after internalization, 
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PICK1 promotes GluA2 internalization and retention in intracellular compartments during 
LTD. The affinity of GRIP1/2 and PICK1 for GluA2 is regulated by the phosphorylation status 
of serine 880 within the AMPAR subunit (Image 1-C). During LTD the activation of PKC 
triggers ser880 phosphorylation switching the affinity of GluA2 from GRIP1/2 to PICK1 thus 
promoting receptor internalization (101–104). 
 
2.11 AMPAR subunits and disease 
The fine tuning of AMPAR synaptic expression as well as the mechanisms that control their 
trafficking and activity are necessary for proper brain function. Indeed, most neurological 
and neurodegenerative disorders can be linked to AMPAR deregulation that underlies 
synaptic malfunctions. For example, variants of GluA3, which cause loss of GluA3 function 
due to gene deletion, reduced protein expression, or loss of channel current have been 
associated with moderate mental retardation (105). Moreover, reduced synaptic AMPARs is 
one of the earliest biological manifestations of dementia in Alzheimer disease (AD); indeed, 
soluble amyloid-β oligomers disrupts GluA2 trafficking resulting in intracellular retaining of 
the receptor (106). Furthermore, the synaptic loss of GluA2-containing AMPARs in AD results 
in the enhancement of surface-expressed CP-AMPARs and consequent excitotoxicity (107).  
The switch from CI-AMPARs to CP-AMPARs owing to the loss of GluA2-containing receptors 
is implicated in the pathology of many other diseases. In particular, CI- to CP-AMPAR switch 
is the causal factor of neuronal death in ischemia and traumatic brain injury (108). Moreover, 
neurons subjected to epileptic seizures markedly down-regulate GluA2 mRNA and subunit 
expression (109). 
Recently, alterations of the AMPA-receptor mediated neurotransmission have been linked 
with autism spectrum disorders. For instance, loss of the autism-related genes, such as 
Rab39b and Mecp2, results in a preponderant expression of CP-AMPARs at the post-synaptic 
membrane (110, 111).  
These observations suggest that aberrant GluA2 incorporation in AMPARs is strongly 
implicated in neuronal disease and highlight the importance of maintaining the balanced 
expression CP- and CI-AMPARs for neuronal functionality. However, much remains to be 
investigated to fully understand how the pathways involved in AMPAR dynamics are 
modulated, possibly serving as basis for the rationale design of therapeutic interventions. 
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3. RESULTS 
 
 
 
3.1 CDKL5 knock-down differentially affects the expression level of AMPA receptor 
subunits 
As mentioned above, several pieces of evidence suggest that loss of CDKL5 negatively impacts 
on spine number and morphology, as well as on LTP and learning and memory. To date, the 
molecular mechanisms that underlie these phenomena have not been completely 
understood. Therefore, we decided to focus our attention on AMPARs, which play important 
roles in spine dynamics and plasticity-related mechanisms. To address this point, mouse 
primary hippocampal neurons were silenced for Cdkl5 at days in vitro 0 (DIV) with lentiviral 
particles carrying either one of two different shRNAs (sh#1; sh#2), or shLacZ as control. 
AMPAR subunit expression was evaluated after 16-18DIV by Western blotting analysis using 
the signal of neuron-specific Class III β-tubulin (Tuj1) as internal standard. The analyses 
were performed on mature neurons, as already demonstrated by our group by the 
appearance of functional synapses between neurons characterized by GluA2-positive 
dendritic punctae juxtaposed to synapsin 1-positive presynaptic dots from 14 days in vitro 
(15). Lentiviral infection with sh#1 and sh#2 efficiently silenced Cdkl5 expression (sh#1: 
0.364±0,071, p<0.001; sh#2: 0.212±0.051, p<0.001) (Fig. 1A-C). Importantly, Cdkl5-
silcencing significantly reduced AMPAR GluA2 subunit expression with both Cdkl5 shRNAs 
compared to the control (sh#1: 0.544±0.087, p<0.001; sh#2: 0.514±0.045; p<0.001), 
whereas expression of the GluA1 subunit was unaltered (sh#1: 0.89±0.124; sh#2: 
0.987±0.092; p=0.652) (Fig. 1B-C). 
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Fig. 1| CDKL5 knock-down differentially affects the expression level of AMPA receptor subunits. (A) 
Representative WB showing silencing of Cdkl5 expression in primary hippocampal neurons with two different 
shRNAs (#1 and #2) or, as control, shLacZ. Neurons were silenced at DIV0 and harvested at DIV16-18. The WB 
shows also GluA1 and GluA2 levels. Tuj1 was used as loading control. (B) Densitometric quantification of data 
shown in A. Analysis of n>7 independent experiments. Statistical analysis: One-way ANOVA followed by 
Dunnett's multiple comparison test; shCdkl5 vs shLacZ: ***p<0.001. 
 
 
 
 
 
 
 
 
 
 
25 
 
3.2 Altered expression of GluA2 subunit in Cdkl5-silenced neurons rely on post-
transcriptional mechanisms 
To test if AMPAR GluA2 subunit downregulation is due to altered gene transcription and 
mRNA abundance, primary hippocampal neurons silenced for Cdkl5 as above, were 
harvested at DIV16 and processed for mRNA extraction. As expected, RT-qPCR analysis 
revealed that Cdkl5 mRNA levels were dramatically reduced after silencing compared to 
control (sh#1: 0.395±0.126, p<0.01; sh#2: 0.192±0.010, p<0.001), whereas GluA2 mRNA 
levels were not affected (sh#1: 1.173±0.077; sh#2: 0.930±0.207; p=0.472) (Fig. 2). These 
data revealed that Cdkl5-silencing does not alter GluA2 gene expression, thus suggesting that 
reduced GluA2 protein levels rely on a post-transcriptional mechanism. 
 
 
Fig. 2| GluA2 mRNA levels are maintained in Cdkl5-silenced neurons. Quantification of Cdkl5 and GluA2 
mRNA expression in primary hippocampal neurons silenced for Cdkl5 (sh#1 and sh#2) or, as control, LacZ. 
Neurons were silenced at DIV0 and harvested for mRNA extraction at DIV16. Cdkl5 and GluA2 mRNA levels were 
determined by RT-qPCR using the expression of Gapdh as internal standard. Analysis of n>4 independent 
experiments. Statistical analysis: One-way ANOVA followed by Dunnett's multiple comparison test; shCdkl5 vs 
shLacZ: **p<0.01; ***p<0.001. 
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3.3 Cdkl5 knock-down results in increased GluA2 phosphorylation at Serine 880 
To understand the mechanism(s) underlying the post-transcriptional down-regulation of 
GluA2 levels in primary hippocampal neurons silenced for Cdkl5, we considered the 
phosphorylation levels of GluA2 Serine 880 (GluA2pS880). As previously noted, S880 
phosphorylation is a key post-translational modification involved in GluA2 internalization 
and subsequent lysosomal degradation during LTD. GluA2pS880 was thus evaluated after 16-
18 days in vitro by Western blotting analysis as the ratio between phosphorylated and total 
GluA2 levels. Cdkl5 knock-down resulted in increased GluA2 phosphorylation when 
compared to the control sample (sh#1: 2.260±0.198, p<0.001; sh#2: 2.259±0.184, p<0.001) 
(Fig.3 A-B). 
 
 
Fig. 3| Cdkl5 knock-down results in increased GluA2 phosphorylation at Serine 880. (A) WB showing 
GluA2 phosphorylation at Serine 880 (S880) and its total isoform in primary hippocampal neurons silenced for 
Cdkl5 with two different shRNAs (#1 and #2) or, as control, shLacZ. Neurons were silenced at DIV0 and 
harvested for WB analysis at DIV16-18. TUJ1 was used as loading control. (B) Densitometric quantification of 
data shown in A. GluA2pS880 was evaluated as the ratio between the phospho-protein and its total isoform. 
Analysis of n>5 independent experiments. Statistical analysis: One-way ANOVA followed by Dunnett's multiple 
comparison test; shCdkl5 vs shLacZ: ***p<0.001. 
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3.4 Cdkl5-silencing drives internalized GluA2-containing AMPARs to lysosomal 
degradation 
To understand if the post-translational down-regulation of GluA2 could be explained by 
increased lysosomal degradation, we analyzed the co-localization between internalized 
GluA2-containing AMPARs and the lysosomal marker LAMP-1 by using the fluorescence-
based antibody feeding assay. Firstly, silenced primary hippocampal neurons at DIV17 were 
live incubated with an antibody recognizing an extracellular epitope of GluA2 (Fig. 4-A), then 
the cultures were stimulated for 2 min with AMPA (100 µM, in the presence of 50 µM of the 
NMDA receptor antagonist APV) to induce the internalization of surface-exposed GluA2-
antibody complexes. To detect only the intracellular immuno-complexes, extracellular-
bound antibodies were stripped away before fixation and staining for LAMP-1. 
Immunofluorescence analyses revealed a significant increase in the number of GluA2 
punctae in Cdkl5-silenced neurons that mainly co-localized with LAMP-1 positive dots. In line 
with the hyper-phosphorylation at Serine 880 these data, even if still preliminary, might 
indicate that an increased amount of internalized GluA2 is directed towards lysosomal 
degradation in the absence of CDKL5 (Fig. 4-B). 
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Fig. 4| Internalized GluA2 co-localizes with the lysosomal marker LAMP-1 in Cdkl5-silcenced neurons. 
(A) Representative images of surface GluA2 (red) in the soma of primary hippocampal neurons at DIV17, 
silenced for Cdkl5 (sh#2) or shLacZ, after live incubation with an antibody against an extracellular epitope of 
GluA2. (B) Representative images of internalized GluA2 (green) and lysosomal marker LAMP-1 (red) (pseudo-
colors) in the soma of primary hippocampal neurons silenced for Cdkl5 after live incubation with GluA2 
antibody followed by stimulation for 2 min with 100 µM AMPA and 30 min of recovery. Arrows indicate co-
localization between internalized GluA2 and LAMP-1. Scale bar 5 µm. 16 neurons were analyzed in a single 
experiment. 
 
 
 
 
 
 
 
29 
 
3.5 Cdkl5 knock-out neurons and adult hippocampus recapitulate the biochemical 
alterations of AMPA receptor observed in Cdkl5-silenced cultures 
The above data show that the abrupt ablation of CDKL5 interferes with AMPAR expression. 
To understand whether the same defect can be observed also upon the complete absence of 
CDKL5 during mouse brain development, we assayed GluA2 expression and Serine 880 
phosphorylation in primary hippocampal neurons prepared from Cdkl5-null/wild type pups. 
Neurons were prepared at post-natal day 0 and harvested at DIV16 for Western blotting 
analysis. Preliminary data indicated that loss of Cdkl5 impaired GluA2-subunit expression 
(0.69), whereas GluA1-subunit expression was less affected (0.91). Moreover, Cdkl5-null 
cultures showed increased GluA2 phosphorylation at Serine 880 (1.55) (Fig.5 A-B). These 
results, albeit preliminary, suggest that the complete loss of Cdkl5 causes altered levels of 
AMPA receptor subunits; moreover, they validate the data obtained with Cdkl5-silenced 
cultures, demonstrating that the observed effects are specific for CDKL5. In line with the data 
obtained from both Cdkl5-null and -silenced cultures, adult Cdkl5-null hippocampi showed a 
significant reduction of GluA2-subunit expression (KO: 0.598±0.110 vs WT: 1.300±0.228, 
p=0.016), whereas GluA1 levels did not change significantly (KO: 2.180±0.408 vs WT: 
1.254±0.294, p=0.111), suggesting that Cdkl5-related AMPAR defects are present also in vivo 
(Fig. 5 C-D).  
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Fig. 5| AMPAR subunit defects are present in Cdkl5-null neurons and adult hippocampus. (A) WB showing 
GluA1-GluA2 expression levels of WT and Cdkl5-null primary hippocampal cultures harvested at DIV16. The 
WB also shows GluA2 phosphorylation at Serine 880 (S880) and its total isoform. Tuj1 was used as loading 
control. (B) Densitometric quantification of data shown in A. GluA2pS880 was evaluated as the ratio between the 
phospho-protein and its total isoform. (n=1).  (C) WB showing GluA1-GluA2 expression levels of WT and Cdkl5-
null hippocampi at P>60. Tuj1 was used as loading control. (D) Densitometric quantification of data shown in 
C. Statistical analysis: unpaired Student’s t test; sh#2 vs shLacZ: *p<0.05. (WT n=5; KO n=6). 
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3.6 Cdkl5 knock-down impairs membrane exposure of GluA2-containing AMPA 
receptors 
To investigate if the altered AMPAR subunit expression can be mirrored in defective 
membrane insertion, surface and total staining of GluA1- and GluA2-containing receptors 
was performed. Immunofluorescence analyses of primary hippocampal neurons silenced for 
Cdkl5 at DIV0 were carried out at DIV18 with two different shRNAs (sh#1; sh#2) or shLacZ 
as control. When compared to control neurons, Cdkl5 silencing significantly reduced the 
amount of membrane-inserted GluA2-containing receptors (sh#1: 0.722±0.027, p<0.001; 
sh#2: 0.728±0.038, p<0.001), whereas the levels of membrane-inserted GluA1-containing 
receptors were unaffected (sh#1 0.920±0.068; sh#2 0.932±0.087; p=0.548) (Fig. 6A-B).  
This result may be the reflection of the decreased amount of GluA2 total protein content 
described above. Nevertheless, when normalizing the surface pool of GluA2 to the total one, 
expressed as the ratio between surface and total amount of AMPA receptors, we also found a 
significant reduction in neurons silenced for Cdkl5 (sh#1: 0.775±0.043, p<0.05; sh#2: 
0.698±0.066, p<0.01). Conversely, surface-to-total ratio of GluA1 was unaffected in Cdkl5-
silenced neurons (sh#1 1.133±0.080; sh#2 1.053±0.165; p=0.609) (Fig 6A-C). Altogether, 
this indicates that CDKL5 deficiency brings not only to a defect in GluA2 expression but also 
in its specific surfacing and recycling back to the membrane. 
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Fig. 6| Cdkl5 knock-down impairs membrane exposure of GluA2-containing AMPA receptors. (A) Representative images of 
surface and total fluorescence intensity of GluA1 and GluA2 in primary hippocampal neurons at DIV18 silenced for CDKL5 (sh#1 and 
sh#2) or, as control, shLacZ. For cell surface staining antibodies raised against extracellular epitopes were used under no-
permeabilizing conditions. Scale bar 15 µm. (B-C) Quantification of data shown in A; GluA1 and GluA2 immunofluorescence intensities 
were analyzed on MAP2+ and GFP+ segments of dendritic branches. The surface-to-total ratio was calculated as the ratio between 
surface and total GluA1-GluA2 fluorescence intensities from single experiments. Analyses of n>4 independent experiments, n>20 
segments/experiment; Statistical analysis: One-way ANOVA followed by Dunnett's multiple comparison test; shCdkl5 vs shLacZ: 
*p<0.05; **p<0.01; ***p<0.001. 
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3.7 Cell-surface biotinylation assays confirm defective AMPAR expression in Cdkl5-
silenced neuronal cultures 
Cell-surface biotinylation provides a highly sensitive and convenient method to label and 
recover cell surface exposed proteins. We exploited this approach to further confirm the 
altered membrane abundance of AMPA receptors in Cdkl5-deficient cultures. Cell-surface 
biotinylation was performed on primary hippocampal neurons silenced for Cdkl5 expression 
from DIV0-18 with sh#2, or shLacZ as control. Biotinylated proteins were recovered and 
analysed by WB in parallel with a fraction of the total protein extract. The amount of surface 
and total GluA2/GluA1 expression was analysed by Western blotting using the signal of 
GAPDH as internal loading standard. In line with the immunofluorescence studies, Cdkl5-
silencing dramatically reduced GluA2 surface expression compared to control (sh#2: 
0.173±0.027, p<0.001), while GluA1 surface expression showed a lesser but significant 
decrease (sh#2: 0.573±0.109, p=0.017) (Fig. 7A-B). As expected, Cdkl5 knock-down also 
resulted in a significant alteration of the surface-to-total ratio of GluA2 (sh#2: 0.690±0.038, 
p<0.001), calculated as the ratio between biotinylated GluA2 and total protein extract. Even 
if the surface-to-total ratio of GluA1 was decreased it did not reach statistical significance 
(sh#2: 0.710±0.104, p=0.052) (Fig 7A-C). These data confirm a role of CDKL5 in modulating 
both expression and surfacing of GluA2-containing receptors.  Moreover, it is worth noting 
that Cdkl5-silencing resulted also in an altered subunit composition of surface exposed AMPA 
receptors. Indeed, by comparing the ratio between biotinylated GluA2 and GluA1 subunits in 
shLacZ and shCDKL5 neurons, we found that AMPARs in neurons devoid of CDKL5 are 
deprived of membrane GluA2 (sh#2: 0.313±0.064, p<0.001) (Fig 7A-D). Considering that the 
presence of GluA2 plays a crucial role in rendering AMPARs impermeable for calcium ions 
our data suggest that the absence of CDKL5 may significantly alter neuronal calcium 
permeability. 
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Fig. 7| Cell-surface biotinylation assay show altered membrane expression and composition of AMPARs 
in Cdkl5-silenced neurons. (A) WB showing GluA2/GluA1 levels in membrane fractions or total extracts of 
primary hippocampal neurons (DIV18) silenced for CDKL5 (sh#2) or, as control, shLacZ. Membrane fractions 
were purified by biotinylation. GAPDH was used as internal standard. (B-D) Densitometric quantification of 
data shown in A. Analysis of n=3 independent experiments. Statistical analysis: unpaired Student’s t test; sh#2 
vs shLacZ: *p<0.05; ***p<0.001. 
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3.8 Calcium imaging reveals an increased calcium influx through AMPARs in Cdkl5-
deficient neurons 
The depletion of GluA2-containing AMPARs at the neuronal membrane in CDKL5-deficient 
neurons that we observed above is likely to lead to increased calcium permeability. Thus, we 
exploited calcium imaging assays at DIV16 on primary hippocampal neurons silenced for 
Cdkl5 expression at DIV0 with sh#2, or LacZ, as control. Intracellular calcium levels were 
evaluated in resting neurons after the incubation with the fluorescent calcium sensor Rhod-
3. We analysed infected neurons expressing GFP (Fig. 8A) by measuring the area under the 
curve (AUC) (represented in Fig. 8B) of Rhod-3 fluorescence intensity in a selected region of 
the soma (ROI) during a fixed time period. To prevent calcium influx from NMDARs, the 
extracellular solution was supplemented with 100 µM of the NMDAR antagonist APV. The 
results showed that Cdkl5-silenced neurons display significantly higher Rhod-3 levels 
corresponding to an increased calcium influx through AMPARs (sh#2: 4.870x104±1.013x104 
vs shLacZ: 2,445x104±4.762x103, p=0.025) (Fig. 8C); this altered calcium conductance 
strongly support a CDKL5-dependent derangement of surface AMPAR composition. 
 
36 
 
 
Fig. 8| Calcium influx through AMPARs is increased in Cdkl5-deficient neurons. (A) Representative frames 
showing Rhod-3 fluorescence intensity of GFP+ neurons silenced for CDKL5 (sh#2) or LacZ, as control. Scale bar 
5 µm. (B) Representative levels of Rhod-3 fluorescence intensity of selected ROIs over 60 s.  (C) Quantification 
of data shown in (B) expressed as the area under the curves (AUC), calculated as an integral of Rhod-3 
fluorescence intensity over 60 s. Analysis of n>7 neurons per condition from 2 different replicates. Statistical 
analysis: unpaired Student’s t test; sh#2 vs shLacZ: *p<0.05. 
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3.9 Cdkl5 silencing alters spine number and morphology 
Growing pieces of evidence suggest that loss of CDKL5 leads to alterations of spine number 
and morphology both in vivo and in vitro. AMPAR deregulation, as observed in our Cdkl5-
silenced cultures, may contribute to those alterations since several studies revealed the 
importance of GluA2-containing AMPARs for proper spine formation and development (59). 
As expected, primary hippocampal neurons silenced for Cdkl5 with two different shRNAs 
(sh#1; sh#2) were characterized by altered spine density and morphology when compared 
to control neurons. In particular, silencing of CDKL5 caused a significant decrease of spine 
number at DIV18 (sh#2: 4.770±0.650 vs shLacZ: 7.646±0.786, p<0.05; sh#1: 5.697±0.450 vs 
shLacZ, p>0.05) (Fig. 9C). The degree of spine maturation can be defined through 
morphological parameters. In particular, filopodial, thin e stubby spines are considered 
immature spines, whereas mushroom and cup-shaped spines are defined as mature spines. 
Morphological classification of spines in Cdkl5-deficient neurons revealed a significant 
increase in the presence of immature spines (sh#1: 82.76±2.692 vs shLacZ: 43.10±3.357, 
p<0.001; sh#2: 87.81±3.456 vs shLacZ, p<0.001) along with a decreased expression of 
mature spines (sh#1: 17.24±2.692 vs shLacZ: 56.90±3.357, p<0.001; sh#2: 12.19±3.456 vs 
shLacZ, p<0.001) (Fig. 9D). 
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Fig. 9| Cdkl5 knock-down causes altered spine number and morphology. (A) Representative image 
showing the classification of spine maturation based on morphology. Filopodial, thin and stubby spines were 
classified as immature spines, whereas mushroom and cup spines were classified as mature spines. (B) 
Representative image showing spine density and morphology of Cdkl5-silenced cultures with sh#1 and sh#2 
or shLacZ. Scale bar 2 µm. (C) Quantification of spine density of neurons showed in (B). Spine density was 
calculated as the number of spines in 10 µm dendritic segments. (D) Morphological classification of spines 
showed in (B) using the criteria reported in (A). Spine analyses were performed using GFP expression as 
reporter of lentiviral infection. Analyses of 24 dendritic segments from 2 independent experiments. Statistical 
analysis: One-way ANOVA followed by Dunnett's multiple comparison test; shCdkl5 vs shLacZ: *p<0.05; 
***p<0.001. 
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3.10 Wild type CDKL5, but not pathological mutants, promotes surface expression of 
homomeric GluA2 AMPA receptors in COS7 cells 
To further investigate the role of CDKL5 in influencing membrane insertion of AMPARs, we 
utilized COS7 cells that were co-transfected with constructs encoding GFP-GluA2 or GFP-
GluA1 along with wild type Flag-CDKL5_1. Immunofluorescence analysis revealed that, 
despite the successful expression of both GFP-GluA2 and GFP-GluA1 in COS7 cells, only GFP-
GluA2 homomers can undergo membrane insertion (Fig 10A-B). Endogenous CDKL5 is 
detectable in COS7 cells, but at relative low levels compared to neurons and brains (data not 
shown). Despite that, endogenous CDKL5 exert a biological function in this cell line as its 
silencing disrupt the mitotic spindle leading to altered mitosis (Chandola C. et al., under 
revision), as well as alterations in cytoskeleton organization and cell morphology (Barbiero 
I. et al., submitted). Interestingly, GFP-GluA2 surface expression was significantly enhanced 
by Flag-CDKL5 co-transfection (Ctrl vs CDKL5 p<0.05) (Fig. 10C), consistently with a role of 
the kinase in GluA2 membrane insertion. In parallel, we also expressed three different 
pathological CDKL5 derivatives: A40V and C152F are characterized by reduced catalytic 
activity, whereas the truncated derivative ∆781 has increased catalytic activity and is 
constitutively confined within the cell nucleus (Fig. 10A). Of note, neither of these 
derivatives were capable of increasing GFP-GluA2 membrane insertion (p>0.05) (Fig. 10C), 
indicating that this property of CDKL5 is lost both in case of missense and truncating 
pathological mutations. Altogether, these results suggest a possible role of functional CDKL5 
in regulating GluA2-containing AMPA receptor trafficking towards the cell membrane. 
Further analyses will be aimed to investigate the role of pathological CDKL5 derivatives in 
neuronal cultures, as well as their capacity to rescue the AMPARs defects. 
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Fig. 10| CDKL5 promotes surface expression of homomeric GluA2 AMPA receptors in COS7 cells. (A)  
Representative images of immunofluorescent staining for surface and total GFP-GluA2 co-overexpressed with 
wild type Flag-CDKL5 or the indicated pathological derivatives in COS7 cells. Scale bar 20 µm. (B) 
Representative images of surface and total fluorescence staining of GFP-GluA1 co-overexpressed with Flag-
CDKL5 in COS7 cells. For cell surface staining, an antibody raised against an extracellular epitope of GluA2 
(sGluA2) or GluA1 (sGluA1) was used under non-permeabilizing conditions followed by incubation with 
antibodies against either GFP or CDLK5 in a permeabilizing buffer to detect respectively total GluA2 (tGluA2) 
and CDKL5 overexpression. (C) Quantification of data shown in A. The surface-to-total ratio was calculated as 
the ratio between surface and total GluA2 fluorescence intensities from a single experiment. Analysis of n>3 
independent experiments; Statistical analysis: One-way ANOVA followed by Dunnett's multiple comparison 
test; *p<0.05. 
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3.11 GRASP-1 is a novel interactor of CDKL5 
The knowledge of the interacting partners of CDKL5 constitutes a fundamental tool to 
understand the functions of CDKL5 and to predict the biological processes in which the 
kinase is involved. To this end, a Yeast Two-Hybrid (Y2H) screening had previously been 
performed in our laboratory in which the C-terminal tail of hCDKL5_5 (AA 299-1030) was 
used as bait to screen a human adult brain cDNA library. Among the 171 interacting clones 
that were identified, GRASP-1 caught our interest. GRASP-1 is a neuronally-enriched protein 
that was initially isolated as a GRIP1-interacting factor. GRASP-1 has two distinct roles in 
neuronal functions: it is required for proper AMPAR recycling and it is critical for spine 
morphology. The CDKL5 interaction surface within GRASP-1 is localized in the C-terminal 
region (amino acids 588-797) (Fig. 11A). The interaction between CDKL5 and GRASP-1 was 
further confirmed by co-immunoprecipitation experiments both in vitro and in vivo. In 
particular, Flag-CDKL5 and GFP-GRASP-1 co-immunoprecipitate from overexpressing 
HEK293T cells (Fig. 11B). This result was replicated also with transfected COS7 cells (data 
not shown). Importantly, when CDKL5 was immunopurified from P25 mouse brain lysates, 
we could also detect GRASP-1 in the pellet. Interestingly, also Syntaxin 13 co-
immunoprecipitated with CDKL5. Syntaxin 13 is an endosomal SNARE protein involved in 
recycling of endosomal domains and an already known interactor of GRASP-1 (Fig. 11C). 
These results suggest that CDKL5 may participate in a molecular complex that regulates 
endosomal sorting towards the neuronal membrane. 
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Fig. 11| GRASP-1 is a novel interactor of CDKL5. (A) Schematic representation of hCDKL5_5 and hGRASP-1 
with the functional domains and signatures indicated. Casp-3: Casapse-3 cleavage-site; PDZ-like domain. The C-
terminal region of hCDKL5_5 spanning amino acids 299-300 (upper red line) was used as a bait. The region 
encompassing amino acids 588-797 of hGRASP-1 (lower red line) was found to interact with CDKL5. (B) Co-
immunoprecipitation of HEK293T cells transfected with the indicated proteins. Whole cell lysates were 
incubated with anti-GFP antibodies and immunocomplexes and inputs (5% of IP) were evaluated by Western 
blotting using the signal of α-tubulin as internal standard. (n=3). (C) Representative co-immunoprecipitation 
experiment of P25 mouse brain lysates with anti-CDKL5 antibody or unrelated IgGs. Co-immunoprecipitates 
and inputs (5% of IP) were evaluated by Western blotting analysis. STX13: Syntaxin 13. (n=3). 
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3.12 The phosphorylation status of GRASP-1 changes during brain development 
Considering the interaction between CDKL5 and GRASP-1, we hypothesize that the latter may 
be a substrate of the catalytic activity of CDKL5. To date, several serine and threonine 
residues in GRASP-1 have been identified as being phosphorylated in both human and mouse 
brain; however, no reports have so far described a direct involvement of CDKL5 
(www.phopshosite.org) (112). To analyze the phosphorylation status of GRASP-1 during 
development, we performed two-dimensional gel electrophoresis on P5 and P25 wild type 
mouse brain lysates. The basic shift of GRASP-1 in λ-phosphatase (λPP)-treated P5 brain 
lysates suggested the existence of at least one phosphorylated isoform of the protein. 
Interestingly, at P25, much more acidic GRASP-1 isoforms appeared with respect to P5, 
suggesting an increase of its phosphorylation profile in the more mature brain (Fig. 12); this 
is in accordance with the concomitant increasing expression of CDKL5 during early brain 
development. 
 
 
Fig. 12| GRASP-1 phosphorylation changes during brain development. WB showing two-dimensional gel 
electrophoresis of P5 and P25 mouse brain lysates. A P5 brain extract was treated with or without lambda 
phosphatase (λPP). GRASP-1 was detected by immunoblotting; the single spot of intermediate filament NFL was 
used as internal control for alignment (data not shown). λPP treatment resulted in a basic shift of GRASP-1 
isoform/s (black asterisk compared to blue asterisks). At P25 an increased number of GRASP-1 acidic spots (red 
asterisks) were present as compared to P5. (n=1). 
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3.13 Tianeptine normalizes GluA2 subunit expression and S880 phosphorylation in 
Cdkl5-deficient cultures 
Tianeptine (S 1574, [3-chloro-6-methyl-5,5-dioxo-6,11-dihydro-(c,f)-dibenzo-(1,2-
thiazepine)-11-yl) amino]-7 heptanoic acid, sodium salt) is an anti-depressant with known 
memory-enhancing effects as its administration increases long-term memory in rodents 
(113, 114). Of relevance for our purpose, tianeptine has been found to greatly stabilize 
surface AMPARs at the synaptic sites by reducing their surface diffusion through a CamKII-
stargazin-PSD-95 pathway (115). Although the molecular mechanisms by which tianeptine 
favours synaptic plasticity are not known, it is likely to involve the dynamic retention of 
surface AMPARs at the synapse. Against this background, the pharmacological potential of 
tianeptine was tested on the AMPAR defects observed in our Cdkl5-silenced neuronal 
cultures. To this aim, Cdkl5-interfered neurons were treated at DIV11 with 10 µM of 
tianeptine, which was replenished every second day till DIV18, when neurons were 
harvested and processed for SDS-PAGE and Western blotting analysis. Importantly, 
tianeptine treatment completely restored GluA2 expression (sh#2: 0.553±0.045 vs shLacZ, 
p<0.001; sh#2+TIA: 1.067±0.267 vs sh#2, p<0.001; sh#2 vs shLacZ, p>0.05) and reduced 
S880 phosphorylation (sh#2: 1.952±0.124 vs shLacZ, p<0.001; sh#2+TIA: 1.340±0.196 vs 
sh#2, p<0.05; sh#2 vs shLacZ, p>0.05) in neurons silenced for Cdkl5 compared to controls 
(Fig. 13 A-B). These results place tianeptine as an interesting candidate drug for CDKL5 
disorder. 
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Fig. 13| Tianeptine completely normalizes GluA2 subunit expression and S880 phosphorylation in 
Cdkl5-deficient cultures. (A) WB showing GluA2 and S880 phosphorylation in primary hippocampal neurons 
silenced for Cdkl5 (sh#2), treated with 10 µM tianeptine for 7 days and harvested at DIV18. TUJ1 was used as 
loading control. Black asterisk indicates a non-specific signal in CDKL5 immunoblot.  (B) Densitometric 
quantification of data shown in A. GluA2pS880 was evaluated as the ratio between phosphorylated and total 
GluA2 levels. (n=3). Statistical analysis: One-way ANOVA followed by Tuckey's multiple comparison test; 
*p<0,05; ***p<0,001. 
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4. DISCUSSION 
 
 
 
Mutations in the X-linked Cyclin-dependent kinase-like 5 (CDKL5) gene have been linked to 
human neurological disorders such as early epileptic encephalopathy and the Hanefeld 
variant of Rett syndrome (RTT) (14) that share as common features the early onset of 
intractable seizures, severe intellectual disability, autistic traits, hypotonia and some RTT-
like features such as hand stereotypies. Today, however, clinicians agree that the peculiar 
pattern of clinical presentations in CDKL5-mutated individuals represent an independent 
clinical entity, named CDKL5 disorder (8, 9). 
In line with its role in the nervous system, CDKL5 levels are highest in brain where its timing 
of expression correlates with synaptogenesis (18). Several data link CDKL5 with dendritic 
spine development and synaptic activity. The protein is synthesized locally in spines upon 
neuronal activity suggesting that it may have several targets in synaptic structures (15). In 
spines, CDKL5 promotes synaptic stabilization by associating with the post-synaptic 
scaffolding protein PSD95 and phosphorylating NGL1 (28, 29). Importantly, Cdkl5-null mice 
and silenced neurons display decreased spine density as result of impaired spine 
stabilization, defective excitatory activity and impaired long-term potentiation (28, 29, 32, 
33). Moreover, loss of Cdkl5 in mice alters many signal transduction pathways, including that 
of AKT-mTOR, and the phosphorylation profile of some kinases, among which PKA, PKC, and 
PKD that are involved in synaptic plasticity (30). Overall, these data show the importance of 
CDKL5 for proper spine development and function but the molecular network through which 
CDKL5 governs these aspects is far from fully understood. 
 
4.1 CDKL5 knock-down affects GluA2 expression and subunit composition of 
membrane-inserted AMPARs 
Considering all the above, during my Ph.D. studies, I focused my attention on a key 
determinant of synaptic strength and plasticity, the AMPA receptor, the deregulation of 
which could underlie, at least in part, the synaptic defects associated with loss of Cdkl5. 
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To this aim, we took advantage of mouse primary hippocampal neurons silenced for Cdkl5-
expression to study AMPAR expression and composition. Interestingly, we found that Cdkl5 
knock-down resulted in a dramatic decrease in expression of the AMPAR subunit GluA2 in 
mature neurons, whereas GluA1 levels were unaltered.  
It is worth noting that these results were mirrored by primary hippocampal neurons from 
Cdkl5-null embryos and in vivo in hippocampi from adult Cdkl5-null brains; this suggests that 
altered AMPAR subunit expression is specifically due to the loss of Cdkl5. 
As demonstrated by qPCR analyses, GluA2 downregulation in Cdkl5-silcenced neurons is 
independent from its mRNA expression, and is thus likely to rely on post-transcriptional 
mechanisms. Among these, we focused our attention on GluA2 post-translational 
modifications that are widely known to regulate AMPAR dynamics and turnover. In 
particular, phosphorylation at serine 880 (S880) is known to be critical in controlling the fate 
of GluA2. GluA2 homomers, as well as GluA2/GluA3 heteromers, undergo exo- and endo-
cytotic processes (116), which are influenced by the phosphorylation status of S880 that 
modulates the affinity of GluA2 for the PDZ-domain partners GRIP1/2 and PICK1 (117). 
Specifically, upon phosphorylation at S880 by PKC, the affinity of GluA2 for GRIP1/2, which 
stabilizes the surface expression of the receptor, is lost in favour of PICK1 binding that drives 
the receptor towards internalization, intracellular retention in nonrecycling compartments 
and/or lysosomal degradation. Interestingly, we found that Cdkl5 knock-down results in 
hyper-phosphorylation of S880 and in an increased co-localization between internalized 
GluA2 and the lysosomal marker LAMP-1, suggesting that reduced GluA2 levels may be due 
to increased degradation of intracellular-retained receptors. Whether other post-
transcriptional mechanisms regulating GluA2 expression, besides lysosomal degradation, are 
targeted by CDKL5 is still to be investigated. 
Besides the reduced levels of total GluA2 we also found a net loss of GluA2-containing 
synaptic AMPARs. As a matter of fact, Cdkl5-silenced neurons displayed an altered subunit 
composition of membrane-inserted AMPARs, which are deprived of GluA2 and thus enriched 
in GluA1. While GluA1 are calcium permeable and are important for the early phase of 
induction of LTP, the presence of GluA2 in heteromeric AMPARs renders the channel 
impermeable to calcium (Ca2+), thus influencing channel kinetics, conductance and synaptic 
transmission (53, 54) and are required for the maintenance of LTP (118).  These speculations 
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are corroborated by our calcium imaging assays indicating that Cdkl5-deficient cultures are 
characterized by an increased AMPAR-dependent Ca2+ influx, which is likely to affect the 
signalling landscape and, thus, neuronal functionality. We can speculate that the unbalance 
of GluA1/2 subunits inserted into the post-synaptic membranes may be one of the molecular 
mechanisms that impair LTP maintenance as reported in the mouse model (33). 
Several studies have linked the alteration of the relative proportion of Ca2+ permeable (CP)-
AMPAR subunits with pathological states, including autism spectrum disorders and epilepsy. 
For instance, Rab39b-silenced mouse hippocampal neuron showed a reduction of GluA2-
containing AMPARs at the post-synaptic membrane (110). Loss-of-function mutations in the 
X-linked RAB39B gene are associated with intellectual disability, autism spectrum and 
seizures (119). RAB39B is a RAB GTPase that has a key role in blocking the retention of 
GluA2/GluA3 heteromers in the endoplasmatic reticulum and promoting their translocation 
into the Golgi, hence leading to surface expression of Ca2+-impermeable (CI) AMPARs (110, 
119).  
It is striking that hippocampal pyramidal neurons from symptomatic Mecp2-/- mice, which 
recapitulate many features of Rett syndrome, display a preponderant expression of CP-
AMPARs at the post-synaptic membrane. This is consistent with higher total and surface 
GluA1 levels, increased sensitivity to the CP-AMPAR selective inhibitor NASPM on AMPAR-
mediated EPSCs, and their smaller inward rectification (111). The authors proposed a model 
in which higher GluA1 levels result from a gradual accumulation and impaired removal at the 
nascent synapses of Mecp2-/- hippocampal neurons. In particular, increased phosphorylation 
of GluA1 at serine 845, as well as increased expression of the membrane-anchoring molecule 
SAP97, stabilize GluA1 at the synaptic membrane, while the concomitant reduction of the 
early-endosomes molecule EEA1 leads to an impaired endocytosis. Despite that GluA2 
expression levels and surface expression were not investigated in this work, it is worth to 
note that also in the murine model of Rett syndrome, a disease tightly linked to CDKL5 
disorder, GluA2 is reduced in Mecp2 knock-out hippocampal neurons and brains (120, 121). 
Importantly, the increase of GluA1 in Mecp2-/- neurons may contribute to the unbalanced 
expression of CP/CI-AMPARs similarly to what occurs in our silenced neurons where, on the 
contrary, it is the GluA2 subunit to be depleted. It is thus plausible that these defects, despite 
opposite at the beginning, might converge to an overlapping outcome. 
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Overall, the above pieces of evidence have led to propose that the altered composition of 
membrane-inserted AMPARs, which lead to an increased Ca2+ permeability, are critical for 
the onset of several neurological features, such as cognitive impairment and seizures that 
characterize autism spectrum disorders and might thus represent the molecular basis for 
pathological outcomes also of CDKL5 disorder. 
Loss of GluA2-containing AMPARs can affect not only the spine functionality, as shown above, 
but also spine number and morphology. 
Several pieces of evidence suggest that the presence of GluA2 subunits in membrane-inserted 
AMPARs correlated with the number, size and shape of dendritic spines (59, 60). In 
particular, silencing of GluA2 expression in mouse primary hippocampal neurons causes a 
significant reduction of spine density and width, whereas GluA2 overexpression in mature 
neurons increases spine number as well as their size. Surprisingly, neither GluA1 nor GluA3 
overexpression affects the size or number of dendritic spines, suggesting that the spine-
promoting activity seems to be specific for GluA2. 
On that basis, it is tempting to link the reduced spine density and the high degree of spine 
immaturity characterizing not only Cdkl5 deficient neurons (32, 33) to the impaired 
expression of GluA2. Analogously, impaired surface expression of GluA2-containing AMPARs 
in primary hippocampal neurons by the silencing of the autism-related gene Rab39b affected 
spine length and width. 
 
4.2 CDKL5 is involved in molecular pathways that regulate the membrane insertion 
and recycling of GluA2-containing AMPARs 
Cdkl5-silenced cultures displayed a reduced surface to total ratio of GluA2-containing 
AMPARs, suggesting that loss of Cdkl5 can impair the trafficking of the receptor towards the 
membrane and thereby lead to depletion of synaptic GluA2.  
Interestingly, overexpression of CDKL5 in COS7 cells is sufficient for enhanced membrane 
insertion of exogenously expressed GluA2-homomers. This effect cannot be obtained by 
pathological derivatives of CDKL5 such as A40V, C152F and ∆781. Previous in vitro analysis 
from our laboratory showed that the C152F (122) and A40V (unpublished data) derivatives 
are devoid of catalytic activity (24). Conversely, the truncated derivate ∆781 (R781X) showed 
an increased kinase activity together with a constitutive nuclear localization (18). These data 
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suggest that both the kinase activity and the cytoplasmic localization of CDKL5 are necessary 
for promoting the membrane insertion of GluA2-homomers in COS7 cells.  
A previous yeast two-hybrid (Y2H) screening revealed that the C-terminus of CDKL5 can 
hypothetically interact with GRASP-1, a component of the molecular machinery that 
regulates the directionality of endosomal trafficking in neurons. GRASP-1, also known as 
GRIPAP-1 (GRIP1 Associated Protein 1), is a neuron-enriched protein that was found as an 
interactor of the seven PDZ domain-containing scaffolding protein GRIP1 (123), which 
transports and stabilizes GluA2 containing AMPARs at synapses. Despite that GRASP-1 was 
originally found to act as a neuronal Ras GEF in vitro (123), recent conflicting data did not 
find either detectable GEF activity for Ras in vivo, or homology with known rasGEF domains 
(124). Differently, Hoogenraad and colleagues proposed GRASP-1 as a novel Rab4 effector 
(124). The endosomal Rab proteins (Rab5, Rab4, and Rab11) have all been implicated in 
endosomal receptor trafficking (125, 126). Rab5 controls the transport to early 
endosomes/sorting endosomes, whereas Rab4 and Rab11 are involved in the regulation of 
endosomal recycling back to the plasma membrane (127). GRASP-1 was found to be an 
effector of Rab4, coordinating the route of endosomal recycling towards the plasma 
membrane by coupling Rab4-positive endosomes with Rab11-positive recycling endosomes. 
Since GRASP-1 cannot bind directly Rab11, the endosomal coupling is mediated by its 
interaction with an other component of the recycling endosomes, syntaxin 13 (STX13). 
Indeed, STX13 is enriched in Rab11 endosomal fractions and, importantly, is a key 
component of the SNARE core complex involved membrane fusion. Hoogenraad et al. 
proposed a model in which GRASP-1 binds the active form of Rab4 via its N-terminus and 
promotes the fusion with Rab11-positive endosomes binding STX13 via its C-terminus. As a 
matter of fact, mutations in STX13 separate Rab11-positive recycling endosomes from 
Rab4/GRASP-1-positive endosomes. Interestingly, GRASP-1 was found to co-localize with 
internalized AMPARs and GRASP-1 knock-down decreased the recycling of GluA2 subunit 
after AMPA stimulation leading to endosomal exit routes, specifically, towards lysosomal 
degradation; a similar defect is plausible also when CDKL5 is missing, as suggested by our 
data. Moreover, similarly to CDKL5, GRASP-1 silencing decreased the total number of 
synaptic protrusions and mushroom-shaped spines and impairs the late phase of LTP in 
hippocampal slices. 
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In line with the evident role of GRASP-1 for synaptic activity, the GRASP-1 gene has been 
proposed as a novel X-Linked Intellectual Disability (XLID) gene (128). Indeed, duplication of 
a region of Xp11 containing GRASP-1, has been associated with autism with severe 
intellectual disability (129, 130). 
Our analyses showed that CDKL5 and GRASP-1 interact both in vitro and in vivo. Interestingly, 
also STX13 co-immunoprecipitated with Cdkl5 in vivo suggesting that Cdkl5, along with 
GRASP-1 and STX13, may participate in the molecular complex involved in Rab4/Rab11 
endosomal coupling. Considering the interaction between CDKL5 and GRASP-1, we speculate 
that the latter may be a substrate of the catalytic activity of CDKL5, although no reports have 
so far described GRASP-1 phosphorylation. Our preliminary studies indicate that 
phosphorylation of GRASP-1 increases during early brain development concomitantly with 
increased expression of CDKL5 (18). Given the role of GRASP-1 in spines and its increase in 
phosphorylation during the peak of synaptogenesis (131), it is tempting to speculate that 
GRASP-1 phosphorylation is involved in spine development and functionality. We therefore 
find it challenging to address in future studies of Cdkl5-null brains if GRASP-1 is a substrate 
of CDKL5 and if the overlapping phenotypes induced by the absence of either CDKL5 or 
GRASP1 indicate a molecular link between the two proteins. 
It worth noting that the Y2H screening assay revealed that CDKL5 interacts with a region of 
GRASP-1 covering a caspase-3 cleavage site (D595TVD598). An additional regulation of GRASP-
1 by caspase-3 cleavage (123, 132) could separate the N-terminal Rab4 binding domain from 
the C-terminal STX13 binding site, potentially disrupting the coupling between Rab4 and 
Rab11 endosomes. In this regard, CDKL5 binding at the cleavage site, possibly involving an 
event of phosphorylation, could hypothetically protect GRASP-1 from cleavage and thereby 
promote endosomal recycling of GluA2 towards the plasma membrane. 
52 
 
 
 
Image 3| Proposed working model of CDKL5 function in AMPAR composition.  A (1-2) GRASP-1 mediates 
the endosomal coupling between Rab4 sorting endosomes (SE) an Rab11 recycling endosomes (RE) acting as a 
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molecular bridge between Rab4 and STX13. We proposed CDKL5 as a novel interactor of GRASP-1 which may 
participate in the molecular complex that promotes the surface insertion of GluA2-containing AMPARs. (3-4) 
GluA2-containing AMPARs undergo constitutive recycling. Upon phosphorylation at S880 by PKC, GluA2 affinity 
for GRIP-1 is lost in favour of PICK1 which promotes receptor internalization in Rab5 early endosomes (EE). 
(5) Once dephosphorylated, internalized GluA2 undergoes recycling back to the post-synaptic density by the 
interaction with the molecular complex involving GRASP-1 and its binding partners. B (1-2) The absence of 
CDKL5 may disrupt Rab4/Rab11 endosomal coupling, leading to the depletion of CI-GluA2-containing AMPARs 
at post-synaptic sites.  (3-6) The impairment of endosomal recycling back to the membrane drives internalized 
GluA2 towards the endosomal exit route via Rab7 late endosomes (LE) and LAMP-1 lysosomes (LY), where it is 
finally degraded. 
 
To date, no cure exists for CDKL5 disorder and therapies are only aimed at alleviating 
symptoms. The rational design of therapeutic strategies is still hindered by the limited 
knowledge of CDKL5 functions underscoring the importance of unravelling the neuronal 
functions of this kinase.  
The findings described above show that loss of Cdkl5 causes a decreased expression of total 
and surface GluA2 AMPAR subunit that appears to rely on impaired membrane insertion and 
increased degradation. These alterations may explain several neurological features, such as 
cognitive impairment and seizures, that characterize CDKL5 disorder.  
 
4.3 Tianeptine is a promising drug for CDKL5-associated AMPAR defects 
An important aspect is whether these defects may represent novel targets for therapeutic 
intervention. On that basis, we focused our attention on tianeptine, a promising drug that 
was reported to modulate AMPAR-mediated glutamatergic neurotransmission. 
Tianeptine, [3-chloro-6-methyl-5,5-dioxo-6,11-dihydro-(c,f)-dibenzo-(1,2-thiazepine)-11-
yl) amino]-7 heptanoic acid sodium salt, is an antidepressant with structural similarities to 
the tricyclic antidepressant agents but with different pharmacological properties, which 
challenge the traditional monoaminergic hypothesis of depression. Extensive studies 
revealed that tianeptine has no significant binding affinity for classical anti-depressant drug-
directed targets, including 5-HT receptors, dopamine receptors, adrenoceptor, glutamate 
receptors and monoamine transporters (133). Since several studies revealed that the 
glutamatergic signalling is impaired in depressed individuals (134) and that the treatment 
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with classic antidepressants, such as the selective serotonin reuptake inhibitor fluoxetine 
and the monoamine reuptake inhibitor imipramine, potentiate the phosphorylation of 
AMPAR (135, 136), it is likely that the modulation of glutamatergic neurotransmission can be 
linked to the therapeutic impact of the antidepressant. 
Tianeptine is classified as a glutamatergic antidepressant as it can potentiate AMPAR 
signalling by activating CaMKII and PKA via the p38, p42/44 MAPK and JNK pathways, and 
by increasing the phosphorylation of GluA1 at serine-831 and -845 (137). Moreover, 
tianeptine can regulate the trafficking and synaptic content of both GluA1- and GluA2-
containing AMPARs through a CaMKII- and stargazin-dependent mechanism that requires 
the phosphorylation of stargazin and the interaction of the AMPAR/stargazin complex with 
PDZ scaffold proteins such as PSD95 (115). At the molecular level, phosphorylation of 
stargazin promotes the stargazin/PSD95 interaction, which in turn recruits and immobilizes 
AMPARs at post-synaptic sites (138). 
We found that tianeptine treatment rescued GluA2 expression in Cdkl5-silenced neurons. 
Despite the molecular mechanisms are still unknown, we hypothesize that this increase may 
rely on an increased synaptic retention of GluA2-containing AMPARs, leading to decreased 
internalization and degradation. This model is in agreement with the concomitant decrease 
of S880 phosphorylation. Further analyses will be aimed to investigate the subunit 
composition of membrane-inserted AMPARs in tianeptine-treated Cdkl5-silenced neurons. 
Of interest, Chu and colleagues showed that tianeptine also exerts neurotrophic effects by 
promoting neurite outgrowth and synapse formation, as well as synapse homeostasis in 
hippocampal neurons (139). These results were supported by a proteomic analysis, which 
identified several differentially expressed proteins involved in neurite growth, 
synaptogenesis and synaptic homeostasis. Among them, tianeptine treatment induced the 
downregulation of BCBP and ADIP, which are negative regulators of synapse formation, and 
calpain. Interestingly, calpain is a Ca2+-activated proteinase, that once activated by elevated 
calcium influx, causes the degradation of many synaptic proteins and contributes to the 
pathophysiology of various neurological disorders (140, 141). The tianeptine-induced 
downregulation of calpain may therefore protect neurons from Ca2+ overloading.  
Overall, these data suggest that besides rescuing GluA2-subunit expression and 
phosphorylation in Cdkl5-silenced culture, tianeptine treatment may exert therapeutic 
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effects on spine abnormalities and contribute by regulating Ca2+ homeostasis. Based on our 
results, we find it important with future studies to test the therapeutic potential of tianeptine 
in preclinical studies of Cdkl5-null mice. 
 
4.4 Conclusions 
In this dissertation we proposed CDKL5 as a novel regulator of AMPAR composition and 
trafficking. Our results showed that the impaired expression of GluA2 containing AMPARs 
can be involved in the synaptic alterations and cognitive deficits associated with CDKL5 
disorder. Further analysis will be required to better characterize the involvement of CDKL5 
in the molecular complex that coordinates the endosomal sorting of AMPARs towards the 
plasma membrane, paving the way for new target directed therapeutic approaches. With this 
aim, we have already identified tianeptine as a promising drug for the treatment of CDKL5-
associated AMPAR defects. 
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5. EXPERIMENTAL PROCEDURES 
 
Antibodies — The following antibodies were used: 
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HRP-conjugated goat anti-mouse and -rabbit secondary antibodies for Western blotting were 
from Thermo Scientific. Secondary Alexa Fluor anti-rabbit, -mouse and -chicken antibodies 
for immunofluorescence experiments were from Invitrogen. 
 
Plasmids and constructs — pCMV-Flag2B-CDKL5, expressing the human CDKL5_1 isoform 
has been described elsewhere (142). pCMV-Flag2B-CDKL5 (A40V; C152F; ∆781) 
pathological derivatives were generated by site-directed mutagenesis using the QuickChange 
site-directed mutagenesis kit (Stratagene). pcDNA3-GFP-GluA1/2 constructs were kindly 
provided by Prof. Richard L. Huganir. pGW1-GFP-GRASP-1 construct was kindly provided by 
Prof. Casper C. Hoogenraad. Lentiviral vectors to silence endogenous CDKL5 were generated 
by cloning double stranded oligonucleotides into the HpaI and XhoI sites of pLentiLox 3.7 
(pLL 3.7). The target sequences of the shRNAs are as follows: shCDKL5#1: 
CTATGGAGTTGTACTTAA; shCDKL5#2: GTGAGAGCGAAAGGCCTT. As control, a shLacZ 
construct, directed against β-galactosidase, was used. All PCR derived constructs were 
sequence verified. 
 
Cell cultures and transfections — COS7 and HEK293T cells were maintained in DMEM 
[Dulbecco's Modified Eagle Medium supplemented with 10% Fetal Bovine Serum, 2 mM L-
Glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich)] at 37°C 
with 5% CO2 in a humidified incubator. Cells were seeded at a density of 7,000 cells/cm2 or 
100,000 cells/ cm2 respectively for immunofluorescence studies or immunoprecipitations. 
Transfections were performed 24 h after plating by using Lipofectamine 3000 (Invitrogen) 
according to manufacturer’s instructions. Cells were fixed or harvested 24 h after 
transfection. 
 
Mice — CD1 and C57BL/6 mice were housed and treated according to the regulations of 
mouse welfare and ethics and with the approval of the institutional animal care and use 
committee of the University of Insubria. 
 
Preparation of primary hippocampal cultures — Primary hippocampal cultures were 
prepared from brains of CD1 mouse embryos at 17 days (E17), considering the day of the 
58 
 
vaginal plug as embryonic day 0. The mice were sacrificed by cervical dislocation, then 
embryos were recovered and the hippocampi were rapidly dissected. After washing in HBSS 
(Gibco), the hippocampi were dissociated by 15’ incubation at 37°C in 0.25% trypsin (Sigma 
Aldrich). The cells were suspended in Dissection Medium [Dulbecco's Modified Eagle 
Medium (DMEM) (Sigma-Aldrich), 10% horse serum (Euroclone), 2 mM L-Glutamine 
(Sigma), 1 mM Sodium Pyruvate (Gibco)] to block the action of the trypsin. Finally, the cells 
were plated on poly-L-lysine hydrobromide coated dishes (0.1 mg/ml) or glass coverslips (1 
mg/ml) at high density (42,000 cells/cm2) in Neurobasal Medium [Neurobasal Medium 
supplemented with B27 (Gibco) and 2 mM L-Glutamine]. After 4 days in vitro (DIV4), 
cytosine-1-β-D-arabinofuranoside (Sigma-Aldrich) was added to cultured neurons at final 
concentration of 2 µM to prevent astroglial proliferation. Primary hippocampal neurons were 
maintained in a humidified incubator with 5% of CO2 at 37°C. 
 
Cdkl5 silencing —Recombinant lentiviruses were produced by cotransfecting HEK293T 
cells, grown in 150 mm dishes, with the packaging vectors pVSV-G, pMDL, pREV and either 
pLL3.7-shCDKL5#1, pLL3.7-shCDKL5#2, or pLL3.7-shLacZ using calcium phosphate. The 
viral particles were harvested 36 h post-transfection and concentrated by ultracentrifugation 
with SW32 rotor (Beckman Instruments) at 20,000 rpm for 2 h. Viruses were resuspended 
in PBS and stored at -80°C. Cultured hippocampal neurons were infected at DIV0, 2 h after 
plating. 
 
Western blotting (WB) — Western blotting was performed using standard methods. 
Samples in Laemmli Buffer were separated by 8-10% SDS-PAGE [Acrylamide/Bis-acrylamide 
solution 37.5:1 (Euro-Clone)], transferred to nitrocellulose membranes and blocked in 5% 
skimmed milk in Tris-Buffered Saline-Tween-20 (TBS-T): 20 mM Tris-HCl pH 7.5, 150 mM 
NaCl, supplemented with 0.2% Tween-20 (Sigma-Aldrich). Blots were incubated with 
primary antibodies in Blocking Solution overnight at 4°C, then washed in in TBS-T and 
incubated with horseradish-conjugated secondary antibodies in Blocking Solution. After 
extensive wash, blots were developed with chemiluminescence-based detection system (StoS 
PSD, Genespin) coupled to G:BOX Chemi Imaging System (Syngene). Densitometric 
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evaluated as the ratio between phospho-proteins and their non-phosphorylated total 
isoforms. 
 
Gene expression analysis — Total RNA from hippocampal neurons was isolated using 
TRIzol Reagent (Invitrogen) according to manufacturer’s instructions. Purified RNA was 
quantified by fluorometric assays with Qubit (Quant-iT RNA HS Reagent, Molecular Probes). 
To asses RNA quality, 300 ng of sample were resuspended in denaturing RNA Sample Buffer 
(20% loading dye, 20% formamide) and incubated at 60°C for 10’, thereafter RNA was 
separated through 1% agarose gel electrophoresis. cDNA was synthetized from 500 ng of 
RNA using iScript Select cDNA Synthesis Kit (Bio-Rad) as indicated by manufacturers. 
Quantitative Real-Time PCR was performed by using 1/20th of volume of revers transcription 
reaction and SYBR Select Master Mix (Applied Biosystems) with a real-time cycler BioRad/MJ 
Research Chromo4. Each sample was assayed in triplicate. The data were analyzed using the 
ΔΔCt method. A melting curve was automatically generated for each sample and confirmed 
that a single amplicon was generated in each reaction. 
The following primers were used: 
 
 
 
Immunofluorescence (IF) — Primary hippocampal neurons plated on glass coverslips were 
fixed at DIV 18 with 4% paraformaldehyde/PBS for 15 minutes and incubated with Blocking 
Solution (5% horse serum in PBS in the presence or absence of 0.2% Triton X-100) for 1h at 
room temperature, and then with primary antibodies overnight at 4°C in blocking solution. 
Primary antibody raised against extracellular epitopes of GluA1-GluA2 were used for the 
surface–expressed AMPARs. The addition of 0.2% Triton X-100 was omitted for the detection 
of surface-expressed receptor proteins. After washing in PBS, the neurons were incubated 
with secondary antibodies (Molecular Probes) for 1 h at room temperature. Coverslips were 
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mounted for microscopy using ProLong Gold antifade reagent (Molecular Probes). GluA1 and 
GluA2 immunofluorescence intensities were analysed on a fixed region of MAP2+ dendritic 
branches of GFP positive neurons. The surface-to-total ratio was calculated as the ratio 
between surface and total GluA1-GluA2 fluorescence intensities from neurons grown on 
different glass coverslips but belonging to the same experiment. 
Spine morphology and number were analysed on MAP2+ dendritic branches of neurons at 
DIV18 using GFP expression to highlight the neuronal structure. 
COS-7 cells grown on glass coverslips were fixed 24h after transfection and processed 
similarly to hippocampal neurons for surface and total AMPAR-staining. The surface-to-total 
ratio was calculated as the ratio between surface and total GluA1-GluA2 fluorescence 
intensities from single cell area.  
Images were captured using a x60 or x100-oil immersion objective coupled to an Olympus 
BX51 Fluorescence microscope equipped with Retiga R1 (QImaging) CCD camera. 
Fluorescence quantifications were performed with Image J software. 
 
Antibody feeding — The current fluorescence-based antibody feeding assay was adapted 
from Hoogenraad et al. (124). Primary hippocampal neurons (DIV 17) were live labelled for 
GluA2 subunits with a mouse monoclonal antibody against an extracellular epitope at a 
concentration of 10 µg/ml by incubating coverslips in conditioned medium for 10 min at 
37°C. After a brief wash in prewarmed DMEM, neurons were alternatively fixed for surface 
staining or processed for subsequent stimulation. To induce AMPAR internalization, cultures 
were either stimulated for 2 min with 100 µM AMPA + 50 µM APV (selective NMDA receptor 
antagonist) or vehicle, as control, then returned to conditioned medium and incubated for 30 
min. The remaining surface anti-GluA2 antibody was stripped away by incubation in 
stripping buffer (0.5 M NaCl/ 0.2 M acetic acid in PBS) on ice for 4 min and washed 
extensively with ice-cold PBS. Finally, neurons were fixed with 4% paraformaldehyde/PBS 
for 15’ at room temperature. Surface or internalized GluA2-subunits were detected with anti-
mouse fluorescent secondary antibodies. Coverslips were pre-incubated with LAMP-1 
antibody overnight at 4°C for the co-localization with internalized GluA2. 
 
61 
 
Cell-surface protein biotinylation — Primary hippocampal neurons (DIV 18) were washed 
with HBSS-glucose (HBSS supplemented with 1% glucose) and then incubated with EZ-link 
sulfo-NHS-SS-Biotin (0,75 mg/ml in HBSS-glucose) for 25 min at 4°C to prevent receptor 
internalization. Unreacted biotin was quenched with Quenching Solution (1% BSA in HBSS-
glucose) for 10 min at 4°C. After washing, hippocampal neurons were lysed in RIPA Buffer 
(50 mM Tris-HCl pH 8, 150 mM NaCl, 1mM EDTA, 1% di Triton X-100, 1% sodium 
deoxycholate, 0,1% SDS and supplemented with PIC) for 1 h at 4°C on a rotating wheel. 
Lysates were clarified by centrifugation at 16000 g for 15 min at 4°C and the supernatants 
were collected and quantified with BCA assay (Thermo Scientific). 200 μg of protein extract 
were incubated with UltraLink Streptavidin beads (Thermo Scientific) in RIPA Buffer on 
rotating wheel for 2 h at 4°C. Cell-surface biotinylated proteins were pulled-down by 
centrifugation, washed in RIPA Buffer and analysed by Western blotting. 
 
Calcium Imaging — Primary hippocampal neurons at DIV 16 were loaded with calcium-
sensitive dye by incubation in 10 μM of Rhod-3 (Molecular Probes) in KRH (Krebs’–Ringer’s–
HEPES) (125 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM HEPES, 6 mM 
glucose, 2 mM CaCl2, pH 7.4) according to manufacturer’s instructions. To prevent calcium 
influx from NMDARs the extracellular solution was supplemented with 100 µM of the NMDAR 
antagonist APV. After rinses in KRH, coverslips were mounted in recording chambers that 
were placed on the stage of an UltraVIEW ERS Spinning Disk Confocal microscope 
(PerkinElmer). Images were captured using a x40 oil immersion objective. Time-lapse 
recording of calcium dynamics was performed with fixed exposure time and excitation 
intensity with an acquisition rate of 1 Hz for 60 sec. Calcium dynamics were measured with 
Image J software selecting Regions Of interest (ROIs) that were drawn on the cell cytoplasm. 
 
Pharmacological treatments — Primary hippocampal neurons were treated at DIV11 with 
Tianeptine in conditioned medium at the final concentration of 10 μM and replenished every 
second day (DIV13, DIV15, DIV17) till DIV18 when neurons were harvested for Western 
blotting analysis. 
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Yeast two-hybrid screening — The yeast two-hybrid (Y2H) screening was performed by 
Hybrigenics Services, S.A.S, Paris, France (http://www.hybrigenics-services.com). The C-
terminus of human CDKL5 (amino acids 299–1030; GenBank accession number gi: 
83367068) fused to the Gal4 DNA-binding domain and expressed from the inducible pB35 
vector, was used as bait to screen a random-primed Human Adult Brain cDNA library 
constructed into pP6. 113 million clones (11-fold the complexity of the library) were 
screened using a mating approach with Y187 (MATα Gal4Δ Gal80Δ ade2-101 his3 leu2-3,-
112 trp1-901 ura3-52 URA3::UASGAL1-LacZ, (met-)) and CG1945 (MATa Gal4-452 Gal80-
538 ade2-101 his3-D200 leu2-3,112 trp1-901 ura3-52 lys2-801 URA3::Gal4 17mers (X3)-
CyC1TATA-LacZ lys2::GAL1UAS-GAL1TATA-HIS3 cyhR) yeast strains. A total of 171 His+ 
colonies were selected on a medium lacking tryptophan, leucine, methionine and histidine. 
The prey fragments of the positive clones were amplified by PCR and sequenced at their 5’ 
and 3’ junctions. The resulting sequences were used to identify the corresponding interacting 
proteins in the GenBank database (NCBI) using a fully automated procedure. A confidence 
score (PBS, for Predicted Biological Score) was attributed to each interaction as previously 
described (143). 
 
Immunoprecipitation (IP) — HEK293T and mouse brains were lysed on ice for 30 min with 
Lysis Buffer: Lysis Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1% Triton X-100, supplemented with protease inhibitor (PIC, Sigma-Aldrich) and 
phosphatase inhibitor (PhosStop, Roche) cocktails. Lysates were clarified by centrifugation 
at 16000 g for 15 min at 4°C and the supernatants were collected and quantified with 
Bradford assay (Bio-Rad). Exogenously expressed GPF-GRASP was immunoprecipitated 
from 400 µg of HEK293T cell extract with 0,6 µg of anti-GFP antibody.  For in vivo 
immunoprecipitations, 1 mg of brain extract was incubated with 1 μg of anti-CDKL5 antibody, 
or unrelated IgGs as control. Lysates were incubated on rotating wheel overnight at 4°C. The 
immunocomplexes were immunoprecipitated with Protein G Agarose (Invitrogen), then 
washed in Lysis Buffer and analysed by Western blotting. 
 
Two-Dimensional Isoelectric Focusing — Brains from post-natal day 5 and 25 (P5 and 
P25) were isolated and lysed in UTC buffer (7 M urea, 2 M thiourea, 4% CHAPS). 
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Approximately 200 μg of extract were loaded on 7 cm IPG DryStrips with a linear 4–7 pH 
gradient and isoelectric focusing performed with an IPGphor II apparatus (GE Healthcare) 
according to the manufacturer’s instructions. Subsequent SDS-PAGE was performed using 
8% gels and proteins were detected by Western blotting. Phosphatase treatment was done 
by adding 100 units of Lambda Protein Phosphatase (λPP; New England Biolabs) to the 
extract diluted in 2 ml 0.1% SDS, 0.1 mM MnCl2, and 1x phosphatase-buffer. After an 
overnight incubation at 30°C the samples were concentrated with Ultracel 10K centrifugal 
filters (Millipore) and subjected to isoelectric focusing. 
 
Statistical Analysis — All values are expressed as the mean±SEM. The significance of results 
was evaluated by Student's t test, one-way ANOVA followed by Dunnett’s or Tuckey’s 
multiple comparison test when appropriate. 
 
Nomenclature - CDKL5 written in upper case letters refers to the human protein, whereas 
Cdkl5 in lower case letters refers to the murine counterpart.  CDKL5 and Cdkl5 reported in 
italics indicate, alternatively, the human and the murine genes and transcripts.
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